Akero executives point to advanced fibrosis patients for MASH drug

Akero Ther­a­peu­tics ex­pects its promis­ing ex­per­i­men­tal MASH drug will be used to treat pa­tients with ad­vanced fi­bro­sis if it re­ceives FDA ap­proval, liken­ing MASH to the dense di­a­betes mar­ket.

Ear­li­er this week, Akero shared mid-stage da­ta that showed its meta­bol­ic dys­func­tion-as­so­ci­at­ed steato­hep­ati­tis (MASH) drug helped im­prove fi­bro­sis. The read­out sent its stock soar­ing on Mon­day, and Akero then an­nounced plans to raise $319 mil­lion in a pub­lic of­fer­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.